Classification criteria for antiphospholipid syndrome and its non-criterial manifestations.

Решетняк, Т. М.; Cheldieva, Fariza

doi:10.25555/thr.2021.4.0990

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Медиана IgG-анти-ФС/ПТ у пациентов с АФС достоверно выше -101,2 Ед/мл [31,5], чем у пациентов без АФС -23,7 [14,8] Ед/мл и контрольной группы (см. рис.…”

Section: результатыunclassified

“…Антифосфолипидный синдром (АФС) является системным аутоиммунным заболеванием, которое характеризуется тромбозом сосудов любого калибра и локализации и/или четко определенными акушерскими осложнениями, возникающими у пациентов с устойчиво позитивными антифосфолипидными антителами (аФЛ) [1][2][3]. К лабораторным критериям АФС относятся: антитела к кардиолипину (аКЛ), к β 2 -гликопротеину I (анти-β 2 -ГП I) любого из изотипов иммуноглобулина (Ig)G или IgM и волчаночный антикоагулянт (ВА) [4,5]. Аутоантитела, не включенные в серологические критерии АФС, которые распознают другие белки свертывания крови или фосфолипид-связанные белки, такие как антитела к комплексу фосфатидилсерин/протромбин (анти-ФС/ПT), предложены в качестве биомаркеров для «серонегативных» пациентов с АФС, тех, которые имели негативные результаты по критериальным антителам [5][6][7].…”

unclassified

“…К лабораторным критериям АФС относятся: антитела к кардиолипину (аКЛ), к β 2 -гликопротеину I (анти-β 2 -ГП I) любого из изотипов иммуноглобулина (Ig)G или IgM и волчаночный антикоагулянт (ВА) [4,5]. Аутоантитела, не включенные в серологические критерии АФС, которые распознают другие белки свертывания крови или фосфолипид-связанные белки, такие как антитела к комплексу фосфатидилсерин/протромбин (анти-ФС/ПT), предложены в качестве биомаркеров для «серонегативных» пациентов с АФС, тех, которые имели негативные результаты по критериальным антителам [5][6][7]. Очевидно, что профили антител при АФС, а не отдельные их значения и разновидности, лучше всего определяют риск развития у пациентов клинических проявлений этого синдрома [8][9][10][11][12].…”

unclassified

See 2 more Smart Citations

Antibodies to the phosphatidylserine/prothrombin complex in the diagnosis of antiphospholipid syndrome

Reshetnyak

Cheldieva

Черкасова

et al. 2022

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To determine the significance of antibodies to the phosphatidylserine/prothrombin complex (aPS/PT) in patients with systemic lupus erythematosus (SLE) antiphospholipid syndrome (APS). Materials and methods. A total of 190 patients were included in the study: 123 (64.7%) with reliable SLE and 55 (29%) with PAPS. The control group included 100 relatively healthy subjects of comparable age. All patients were tested for classical aPL as well as IgG/IgM-anti-PS/PT by enzyme immunoassay. Results. Based on the average values of IgG/IgM aPS/PT of the control group, the levels of positivity were allocated mean (M) + 3 or 5 standard deviations (SD): M+3SD and M+5SD. IgG aPS/PT levels above 73.6 U/ml (M+5SD) were more accurate diagnostic, for IgM aPS/PT above 18.0 U/ml. IgG-aPS/PT were detected in 84 (44%) of 190 patients. Levels above diagnostic levels were detected in 68 (65%) of 104 patients with APS (55 with PAPS and 59 with SLE+APS). Thrombosis was significantly more common in patients with IgG aPS/PT compared with patients negative for IgG aPS/PT. Arterial but not venous thrombosis was associated with IgG aPS/PT positivity. Conclusion. The frequency of detection of IgG aPS/PT in the examined patients was 44%, IgM aPS/PT 29% and their combination 19% of 190 patients. Half of the patients with probable APS had positive IgG aPS/PT and third IgM aPS/PT. Median IgG aPS/PT were significantly higher in patients with APS compared to patients without APS and the control group. Thrombosis was associated with IgG aPS/PT. Arterial thrombosis was significantly more frequently reported in patients with IgG aPS/PT. The sensitivity of IgG aPS/PT for reliable APS at levels greater than 73.6 units/ml was 59%, specificity 92%, for IgM aPS/PT 35% and 91%, respectively.

show abstract

Section: результатыunclassified

unclassified

See 1 more Smart Citation

Antibodies to the phosphatidylserine/prothrombin complex in the diagnosis of antiphospholipid syndrome

Reshetnyak

Cheldieva

Черкасова

et al. 2022

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

“…К ним относят сетчатое ливедо (livedo reticularis), кожные язвы, тромбоцитопению, микроангиоэнцефалопатию, нефропатию (при исключении других заболеваний), патологию клапанного аппарата сердца (неинфекционный эндокардит Либмана -Сакса), антитела к комплексу фосфатидилсерин/ протромбин (аФс/Пт), антитела к домену I β 2гликопротеина 1 (β 2 ГП1), IgA аФЛ, антитела к аннексину и др. [3,6]. Один из этих признаков может быть в дебюте единственным проявлением, определяющим тактику лечения и последующий исход заболевания.…”

Section: Introductionunclassified

Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosus

Cheldieva¹,

Reshetnyak²,

Shumilova³

et al. 2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Introduction. The Global Antiphospholipid Syndrome Score (GAPSS) is a tool proposed to quantify the risk of clinical manifestations associated with antiphospholipid antibodies (aPL) and certain cardiovascular risk factors.Objective. To validate GAPSS in a cohort of patients with systemic lupus erythematosus in Russia.Material and methods. 115 patients with SLE were included in the study, including 51 (44%) patients with systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS), 14 (12%) – SLE with aPL, and 50 (44%) – SLE.Results. There was a history of thrombosis in 58 (50%) patients with 115, of them 14 (24%) had arterial thrombosis, 29 (50%) – venous, 15 (26%) – combined. Pregnancy against the background of the disease occurred in 43 women included in the study. Of them, 29 (67%) had obstetric pathology. Patients with thrombosis and obstetric pathology had a GAPSS score of 7.17±5.64, versus 4.48±4.55 without these manifestations (p=0.0003). There was a significant association between GAPSS levels and thrombosis – patients with thrombosis had a GAPSS of 7.31±5.70, those without thrombosis – 4.00±4.81 (p=0.001). GAPPS values were higher in arterial thrombosis compared to venous thrombosis (10.40±25.30 versus 5.82±5.28; p=0.01). GAPSS levels ≥6 and ≥10 were analyzed to select GAPSS values at which a high risk of recurrent thrombosis and/or obstetric pathology could be indicated. All GAPSS levels had a significant association with clinical manifestations of APS. The quality of GAPSS by ROC analysis showed an area under the curve (AUC) for GAPSS of 0.697.Conclusion. GAPSS can be used to assess the risk of recurrence or development of thrombosis and/or obstetric pathology in patients with SLE in the Russian Federation. The GAPSS ≥6 values should be used to stratify patients with SLE into high risk group for recurrence of vascular complications. Further prospective follow-up is needed to confirm the value of GAPSS.

show abstract

“…[32,33]. У всех пациентов изначально и у выживших через 15 лет были оценены активность СКВ по SLЕDAI-2К (Systemic Lupus Erythematosus Disease Activity Index в модификации 2К) [34], индекс повреждения SDI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index) [35], особенности полиорганного поражения, наличие АФС согласно общепринятым международным критериям [36][37][38] Результаты. В исследование было включено 68 больных СКВ, среди которых преобладали женщины (98,5%).…”

unclassified

Survival and lethal outcomes in Orenburg population of patients with systemic lupus erythematosus

Lazareva,

Bugrova,

Artemova

et al. 2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Currently, the prognosis for systemic lupus erythematosus (SLE) has improved significantly, but the relative risk of death in these patients is stillhigher than in the general population. Thrombotic complications are one of the leading causes of death in SLE. Objective: to analyze the survival rate and structure of lethal outcomes in Orenburg population of patients with SLE, including deaths due to thrombotic complications. Material and methods. A two-stage study of SLE progression and patient survival was conducted from 2007 to 2022. Clinical signs of the diseasewere analyzed in all patients at baseline (n = 68) and in survivors (n = 50) after 15 years. The median age at the time of enrolment in the study was 35 [29; 45] years, the disease duration – 7.5 [3; 13.5] years. During the second stage, the characteristics of the course of the disease in the survived patients and the causes of death in those who died over 15-year period were determined. Results and discussion. The 10-, 15- and 20-year survival rates in Orenburg population of patients with SLE reached 98.5, 95.5 and 86.3%, respectively. During this period, 18 (26.5 %) deaths were registered, the median age of the deceased was 48.5 [39; 57] years, and the duration of the disease was 22 [16; 30] years. The most common causes of death were thrombotic complications (n = 14, 78 %) due to antiphospholipid syndrome, lupus nephritis, and arterial hypertension. Less frequently, infectious complications were the cause of death (n = 4, 22 %). Patients with thrombotic complications had a 20-year survival rate of 80.2% that was significantly lower than in the SLE group without thrombosis. Conclusion. The results obtained allow to consider the presence of thrombotic complications in patients with SLE in Orenburg population as an unfavorable prognostic factor.

show abstract

Classification criteria for antiphospholipid syndrome and its non-criterial manifestations.

Cited by 3 publications

References 0 publications

Antibodies to the phosphatidylserine/prothrombin complex in the diagnosis of antiphospholipid syndrome

Antibodies to the phosphatidylserine/prothrombin complex in the diagnosis of antiphospholipid syndrome

Global antiphospholipid syndrome score (GAPSS) in patients with systemic lupus erythematosus

Survival and lethal outcomes in Orenburg population of patients with systemic lupus erythematosus

Contact Info

Product

Resources

About